Daflon is a venotonic based on purified micronized flavonoid fraction (diosmin 450 mg, hesperidin 50 mg). It acts on the tone of the venous walls and reduces capillary permeability, which alleviates symptoms related to chronic venous insufficiency: heavy legs, pain, edema. The medication does not eliminate visible varicose veins but targets the functional signs that accompany venous disease.
Mechanism of action of Daflon on venous circulation
Diosmin and hesperidin are plant-derived flavonoids. In micronized form, their intestinal absorption is significantly improved compared to non-micronized forms. Once in the bloodstream, these molecules enhance the resistance of the venous walls and decrease blood stasis in the lower limbs.
Read also : How to Start Investing and Grow Your Money Effectively
Specifically, Daflon increases venous tone, which promotes the return of blood to the heart. It also reduces inflammation at the level of damaged venous valves, a central phenomenon in the progression of venous insufficiency. This dual effect, both tonic and anti-inflammatory, explains why the medication is prescribed for both heavy legs and hemorrhoidal crises.
To know precisely how long Daflon acts on varicose veins, it is necessary to distinguish between symptomatic relief (a few days) and the benefit on established venous disease (several weeks of continuous treatment).
Related reading : How to Choose the Best Air Cooler for a Refreshing Summer
Action time of Daflon: mild symptoms and established varicose veins
The first effects on the sensation of heaviness and leg pain generally appear within the first two weeks of treatment. This time corresponds to the duration needed for the concentration of flavonoids to reach a sufficient level in the venous tissues.
For established varicose veins with edema, the treatment lasts longer. The usual dosage is two tablets per day (one at noon, one in the evening, during meals). A treatment cycle often lasts several months, depending on the severity of the symptoms and individual response.
It should be emphasized that dosage alone does not resolve one point: Daflon treats the symptoms of venous insufficiency, not the varicose veins themselves. The dilated and tortuous veins remain in place. The medication acts on pain, swelling, and the sensation of heaviness, which improves daily comfort but does not replace interventional management if the varicose veins progress.
Daflon combined with compression and endovenous treatments
Prescribing Daflon alone for moderate to severe venous insufficiency limits results. The combination with compression stockings remains the cornerstone of conservative treatment. Mechanical compression assists venous return while the venotonic acts on the vein walls and local inflammation.
More recent data show an interest in combining Daflon with endovenous therapies (laser or radiofrequency). A multicenter prospective study published in the Journal of Vascular Surgery in January 2026 reports a significant reduction in varicose vein recurrences in postoperative follow-up, with a qualitative improvement in venous healing in about 70% of patients treated with this combination.
This result suggests that the venotonic, taken continuously after an intervention, prolongs the benefit of the technical procedure. The duration of postoperative treatment remains to be specified on a case-by-case basis with the physician, but several months of intake seem necessary to observe this protective effect.
Efficacy of Daflon in obese or diabetic patients
Obesity and type 2 diabetes worsen venous insufficiency through distinct but converging mechanisms. Overweight increases pressure in the veins of the lower limbs. Diabetes alters microcirculation and slows tissue healing, including the venous walls.
In these patients, the effectiveness of Daflon may be compromised in several ways:
- The intestinal absorption of flavonoids is modified by metabolic disorders associated with diabetes, which may reduce the bioavailability of the active ingredient
- Chronic low-grade inflammation, present in the majority of obese patients, limits the local anti-inflammatory effect of the medication on the venous valves
- Compliance with treatment (wearing compression, physical activity, regular intake of the medication) is often lower in this demographic profile, which delays results
A venotonic alone does not compensate for the mechanical effects of significant excess weight. Without weight loss and without appropriate venous compression, the benefit of Daflon remains partial. The treating physician or phlebologist must adjust the overall strategy, not just the medication prescription.
This patient profile, which is constantly increasing, represents a growing share of consultations for venous insufficiency. Adapting treatment to this clinical reality (prolonged duration, close monitoring, systematic combination with compression) directly conditions the results.
Side effects and limitations of prolonged treatment with Daflon
Daflon is generally well tolerated. The most common side effects are digestive: nausea, diarrhea, abdominal pain. They are usually moderate and disappear upon discontinuation of treatment.
The High Authority of Health (HAS) has reassessed the medical benefit of Daflon and deemed it moderate in the treatment of symptoms of venous insufficiency. This classification means that the clinical benefit exists but remains limited, particularly in advanced stages of venous disease. The current reimbursement rate reflects this assessment.
Over a treatment period of several months, two points deserve particular attention:
- The absence of major contraindications does not exempt from regular medical follow-up, especially in patients on anticoagulants or treated for diabetes
- Discontinuation of treatment often leads to a gradual return of symptoms, raising the question of the optimal duration and the interest of repeated courses rather than indefinite continuous intake
- The medication does not slow the anatomical progression of varicose veins: if the disease progresses, an evaluation for an endovenous or surgical procedure remains necessary
The duration of treatment with Daflon therefore depends on the patient’s profile, the severity of symptoms, and associated treatments. Two to three months represents a common cycle, renewable after medical evaluation. In obese or diabetic patients, closer monitoring and a combined approach remain the condition for a tangible result over time.